1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 63629-2016
  5. Product Images: Felodipine

Product Images Felodipine

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. image description - 1 formula
  2. Label - lbl636292016
  3. table 1 - table 1
  4. table 2 - table 2

Product Label Images

The following 4 images provide visual information about the product associated with Felodipine NDC 63629-2016 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image description - 1 formula

image description - 1 formula

Label - lbl636292016

Label - lbl636292016

Felodipine Extended-Release Tablets, USP is a medication to be kept out of children's reach. It contains 10 mg of Felodipine, USP and is dispensed in a tightly sealed, light-resistant container with a child-resistant closure. The tablets are film-coated and come in a pack of 500. It should be stored at 20° to 25°C (68° to 77°F) and protected from light. NILD and Aq pajaqeley are not relevant to the medication.*

table 1 - table 1

table 1 - table 1

This is a tabular representation of two studies evaluating the mean reductions in blood pressure (in mmHg) for different doses of medication. The first study was conducted for 8 weeks and included three different doses of medication: 5mg, 10mg, and 25mg. The second study was conducted for 4 weeks and included two doses, 0mg (placebo) and 20mg. The table also includes the number of patients for each dose and the mean peak and trough response ratios. Placebo response was subtracted, and the note at the end states that a different number of patients were available for peak and trough measurements.*

table 2 - table 2

table 2 - table 2

This is a table showing the percentage of patients experiencing adverse events during controlled trials of Felodipine Extended-Release Tablets as Monotherapy, without regard to causality. The table shows the adverse events experienced in each dosage group (placebo, 2.5mg, 5mg, and 10mg) and the number of patients experiencing the event, with the incidence of discontinuations shown in parentheses. The events are categorized based on body system and include peripheral edema, asthenia, palpitations, nausea, headache, dizziness, and rash among others. The table indicates that most adverse events were more common in the higher dosage groups.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.